Veklury
Payments companies reported to CMS as associated with Veklury. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Veklury, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Veklury
These are the largest totals companies reported as associated with Veklury. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rajkumar Dasgupta | Pasadena, CA | Pulmonary Disease | $95,606.05 |
| Alpesh Amin | Orange, CA | Hospitalist | $93,388.09 |
| Fariborz Rezai | Livingston, NJ | Critical Care Medicine (Internal Medicine) | $85,863.35 |
| Marc Milano | Berkeley Heights, NJ | Emergency Medicine | $72,838.68 |
| Ashraf Elsayegh | Los Angeles, CA | Pulmonary Disease | $65,407.88 |
| Hector Brunet Rodriguez | Shreveport, LA | Infectious Disease | $61,616.89 |
| Neera Ahuja | Stanford, CA | Internal Medicine | $59,673.47 |
| Robert Gottlieb | Dallas, TX | Advanced Heart Failure and Transplant Cardiology | $57,323.00 |
| Patrick Godwin | Chicago, IL | Internal Medicine | $55,735.39 |
| Ngozika Orjioke | East Point, GA | Pulmonary Disease | $43,066.40 |
Prescribed Veklury?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.